Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01053403 · ClinicalTrials.gov registry record · NA
Study of the Effects of MDMA/Ecstasy on Water Regulation, Sleep, and Cognition.
A NA study, sponsored by California Pacific Medical Center Research Institute.
- Completed
- Registry status
- NA
- Development phase
- 12
- Enrollment target
NCT01053403: Completed NA study, sponsored by California Pacific Medical Center Research Institute.
NCT01053403 is a NA study that has completed, run by California Pacific Medical Center Research Institute. The registered enrollment target is 12 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01053403, a NA study, has completed, sponsored by California Pacific Medical Center Research Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of this study is to measure the effects of MDMA on sleep, mood, thinking, and how your body retains water. The researchers are interested in the effects that occur a few hours after taking MDMA as well as effects occurring over the next two days. We will study these effects in a standardized, controlled setting at the Clinical and Translational Science Institute (CTSI) Clinical Research Center (CRC) located at San Francisco General Hospital. The primary hypotheses are: 1. MDMA will induce sleep disruption, as indicated by comprehensive polysomnography, wrist actigraphy, and self-report sleep measures 2. MDMA will alter sodium and water homeostasis by either increasing or blunting the suppression of arginine vasopressin levels and decreasing free water excretion. Effects will be exacerbated by water loading. Secondary hypotheses: 1. Acutely, MDMA will increase both positive and negative arousal, and to increase sociability but not autonomy. 2. Acutely, MDMA will increase risk-taking and willingness to donate money to others in an economic decision making task. 3. MDMA will decrease the stressful effects of talking about a negatively-valenced autobiographical but will increase recall for details for these episodes. 4. MDMA will increase oxidative stress markers and possible ameliorating factors (e.g., ADMA). 5. The short form of the serotonin transported promoter region will be associated with greater acute and discontinuation effects of MDMA.
Interventions
- DRUG 3,4-methylenedioxymethamphetamine or Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2010-04 |
| Est. Completion | 2011-02 |
| Phase | NA |
What the finished NCT01053403 record still lists
NCT01053403 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which 3,4-methylenedioxymethamphetamine or Placebo is the first listed.
NCT01053403 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01053403 about?
NCT01053403 is a clinical study titled "Study of the Effects of MDMA/Ecstasy on Water Regulation, Sleep, and Cognition.". The purpose of this study is to measure the effects of MDMA on sleep, mood, thinking, and how your body retains water. The researchers are interested in the effects that occur a few hours after taking MDMA as well as effects occurring over the next two days. We will study these effects in a standard...
What is the current status of trial NCT01053403?
This trial is currently completed. It is a NA study. The enrollment target is 12 participants. The study started on 2010-04. Estimated completion is 2011-02.
What interventions are being tested in trial NCT01053403?
The interventions under investigation include: 3,4-methylenedioxymethamphetamine or Placebo (DRUG).
Who is sponsoring clinical trial NCT01053403?
This trial is sponsored by California Pacific Medical Center Research Institute, which has 29 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01053403's enrollment target sits among peer trials
12 1913th of 2000 higher than 74 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia